Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Trend | Peers | Company |
|---|---|---|
| Is return on equity increasing? | Yes | No |
| Is net profit margin increasing? | Yes | Yes |
| Is asset turnover increasing? | Yes | Yes |
| Is equity multiplier increasing? | Yes | No |
| Competitors Used |
|---|
| Molecular Partners AG |
| argenx SE |
| Zealand Pharma A/S |
| Genmab A/S |
| DBV Technologies S.A. |
| Return on Equity Benchmarks | ||||||||
| Comparable Companies | ||||||||
| MOLN | ARGX | ZEAL | GMAB | DBV | BSLN | |||
| Return On Equity | ||||||||
| Latest Twelve Months | -40% | NA | -21% | 23% | -198% | 219% | ||
| Fiscal Year - 1 | -30% | -9% | -58% | 15% | -43% | -68% | ||
| Fiscal Year - 2 | 69% | -27% | -111% | 21% | -66% | -31% | ||
| Fiscal Year - 3 | -59% | -19% | -70% | 14% | -64% | 9% | ||
| Fiscal Year - 4 | -78% | -43% | -54% | 30% | -80% | 15% | ||
| Fiscal Year - 5 | -50% | -20% | -48% | 19% | -104% | 28% | ||
| Average | -31% | -23% | -61% | 20% | -93% | 29% | ||
| Median | -45% | -20% | -56% | 20% | -73% | 12% | ||
| Benchmarks | Ticker | |||||||
| Molecular Partners AG | SWX:MOLN | |||||||
| argenx SE | ENXTBR:ARGX | |||||||
| Zealand Pharma A/S | CPSE:ZEAL | |||||||
| Genmab A/S | CPSE:GMAB | |||||||
| DBV Technologies S.A. | ENXTPA:DBV | |||||||
| Financial Performance | ||||||||
| Comparable Companies | ||||||||
| (in millions) | MOLN | ARGX | ZEAL | GMAB | DBV | BSLN | ||
| Latest Fiscal Year | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | Dec-24 | ||
| LTM Period | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Mar-25 | Dec-24 | ||
| Revenues | ||||||||
| Latest Twelve Months | 2 | 2,643 | 56 | 3,231 | 3 | 209 | ||
| Fiscal Year | 5 | 2,248 | 63 | 2,990 | 4 | 209 | ||
| Fiscal Year - 1 | 7 | 1,269 | 343 | 2,440 | 16 | 158 | ||
| Fiscal Year - 2 | 190 | 441 | 104 | 2,088 | 5 | 148 | ||
| Fiscal Year - 3 | 10 | 528 | 109 | 1,288 | 6 | 148 | ||
| Fiscal Year - 4 | 9 | 62 | 192 | 1,660 | 11 | 128 | ||
| Fiscal Year - 5 | 20 | 93 | 41 | 806 | 15 | 134 | ||
| Net Income | ||||||||
| Latest Twelve Months | (59) | 1,064 | (1,186) | 1,140 | (114) | 78 | ||
| Fiscal Year | (54) | 833 | (1,079) | 1,090 | (114) | 78 | ||
| Fiscal Year - 1 | (62) | (295) | (704) | 645 | (73) | 10 | ||
| Fiscal Year - 2 | 118 | (710) | (966) | 785 | (96) | 12 | ||
| Fiscal Year - 3 | (64) | (408) | (755) | 452 | (98) | (7) | ||
| Fiscal Year - 4 | (63) | (608) | (669) | 781 | (160) | (15) | ||
| Fiscal Year - 5 | (36) | (181) | (572) | 325 | (172) | (22) | ||
| Total Assets | ||||||||
| Latest Fiscal Quarter Prior | 186 | NA | 3,587 | 5,305 | 146 | 173 | ||
| Latest Fiscal Quarter | 141 | NA | 9,122 | 6,586 | 51 | 258 | ||
| Fiscal Year | 159 | 6,203 | 9,506 | 6,363 | 66 | 258 | ||
| Fiscal Year - 1 | 198 | 4,542 | 1,980 | 5,227 | 183 | 173 | ||
| Fiscal Year - 2 | 262 | 3,134 | 1,540 | 4,336 | 247 | 221 | ||
| Fiscal Year - 3 | 173 | 2,850 | 2,068 | 3,767 | 147 | 247 | ||
| Fiscal Year - 4 | 188 | 2,279 | 1,762 | 3,470 | 272 | 230 | ||
| Fiscal Year - 5 | 105 | 1,610 | 1,600 | 2,273 | 272 | 221 | ||
| Fiscal Year - 6 | 155 | 663 | 1,230 | 1,298 | 197 | 282 | ||
| Common Equity | ||||||||
| Latest Fiscal Quarter Prior | 169 | 4,098 | 2,838 | 4,700 | 112 | (10) | ||
| Latest Fiscal Quarter | 128 | 5,498 | 8,308 | 5,296 | 3 | 81 | ||
| Fiscal Year | 142 | 5,498 | 8,617 | 5,097 | 27 | 81 | ||
| Fiscal Year - 1 | 176 | 4,098 | 1,593 | 4,682 | 140 | (10) | ||
| Fiscal Year - 2 | 235 | 2,814 | 816 | 3,928 | 194 | (21) | ||
| Fiscal Year - 3 | 107 | 2,534 | 928 | 3,395 | 99 | (59) | ||
| Fiscal Year - 4 | 107 | 1,674 | 1,229 | 3,138 | 205 | (102) | ||
| Fiscal Year - 5 | 54 | 1,180 | 1,243 | 2,109 | 193 | (93) | ||
| Fiscal Year - 6 | 92 | 617 | 1,116 | 1,230 | 139 | (67) | ||